Acadia Pharmaceuticals | ACAD - Capital Social Ordinario

Precio De Mercado
20.61
Cambio Diario
-0.66 -3.10%
Mensual
-10.20%
Anual
17.77%
Q1 Expectativa
19.99




Capital Social Ordinario Cambio Fecha
Acadia Pharmaceuticals USD 169.18M 470K 2025-12
ALKERMES USD 165.61M 503K 2025-12
Alnylam Pharmaceuticals USD 132.38M 585K 2025-12
Biogen USD 146.7M 200K 2025-09
BioMarin Pharmaceutical USD 192.3M 201K 2025-12
Bristol-Myers Squibb USD 2.04B 1.74B 2025-09
Cara Therapeutics USD 2K 3K 2025-03
Corcept Therapeutics USD 105.97M 842K 2025-12
Cytokinetics USD 122.26M 145K 2025-12
Eisai JPY 282.11M 1000 2025-12
Eli Lilly USD 946.83M 354.23M 2025-06
Incyte USD 198.46M 2.33M 2025-12
J&J USD 2.41B 584K 2025-09
Moderna USD 391M 2M 2025-09
Neurocrine Biosciences USD 100.1M 400K 2025-12
Pfizer USD 5.69B 1000K 2025-09
Prothena USD 53.83M 53.29M 2025-09
PTC Therapeutics USD 81.47M 1.54M 2025-12
Sarepta Therapeutics USD 104.96M 196K 2025-12
Ultragenyx Pharmaceutical USD 96.44M 88K 2025-09
Vanda Pharmaceuticals USD 58K 0 2024-12
Vertex Pharmaceuticals USD 254M 0 2025-12